Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jan;60(1):272-4.
doi: 10.1007/s10620-014-3374-1. Epub 2014 Oct 5.

Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir

Perry H Dubin  1 , Seth N Sclair, Rene Rico, Amelia K Boehme, Emerson Y Chen, Paul Martin, William M Lee
Affiliations
Comment

Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir

Perry H Dubin et al. Dig Dis Sci. 2015 Jan.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Price JC, Murphy RC, Shvachko VA, Pauly MP, Manos MM. Effectiveness of telaprevir and boceprevir triple therapy for patients with hepatitis C virus infection in a large integrated care setting. Dig Dis Sci. (Epub ahead of print). - PMC - PubMed
    1. Chen EY, Sclair SN, Czul F, et al. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clin Gastroenterol Hepatol. 2013;11:1014.e2–1020.e2. - PubMed
    1. Kanwal F, El-Serag HB. HCV treatment: The unyielding chasm between efficacy and effectiveness. Clin Gastroenterol Hepatol. 2014;12(8):1381–1383. - PubMed
    1. Hezode C, Fontaine H, Dorival C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132.e4–142.e4. - PubMed
    1. Saxena V, Manos M, Yee H, et al. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis. Aliment Pharmacol Ther. 2014;39(10):1213–1224. - PMC - PubMed

LinkOut - more resources